Transfusion rates after 800 Aquablation procedures using various haemostasis methods

Dean Elterman*, Thorsten Bach†, Enrique Rijo‡, Vincent Misrai§, Paul Anderson¶, Kevin C. Zorn**, Naeem Bhojani**, Albert El Hajj††, Bilal Chughtai‡‡ and Mihir Desai§§

*Division of Urology, University Health Network, University of Toronto, Toronto, ON, Canada, †Department of Urology, Asklepios Hospital Harburg, Hamburg, Germany, ‡Department of Urology, Hospital Quiron Salud, Barcelona, Spain, §Department of Urology, Clinique Pasteur, Toulouse, France, ¶Royal Melbourne Hospital, Melbourne, Victoria, Australia, **University of Montreal Hospital Center, Universite de Montreal, Montreal, QC, Canada, ††Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon, ‡‡Department of Urology, Weill Cornell Medical College, New York Presbyterian, New York, NY, and §§Department of Urology, University of Southern California, Los Angeles, CA, USA

Objective
To determine if athermal methods are as effective in preventing blood transfusions as the use of cautery across various prostate volumes following prostate tissue resection for benign prostatic hyperplasia using Aquablation.

Patients and methods
The current commercial AQUABEAM robot that performs Aquablation therapy was first used in 2014. Since then numerous clinical studies have been conducted in various countries; Australia, Canada, Germany, India, Lebanon, Spain, New Zealand, United Kingdom, and the United States. All of the clinical trial data since 2014 were pooled with the early commercial procedures from France, Germany, and Spain to determine the effectiveness of haemostatic techniques in reducing the transfusion rate in patients after Aquablation.

Results
In all, 801 patients were treated with Aquablation therapy from 2014 to early 2019. The mean (SD, range) prostate volume was 67 (33, 20–280) mL and 31 (3.9%) transfusions were reported. The largest contributing factor to transfusion risk was prostate size and method of traction. There was an increasing risk of transfusions in larger prostates when robust traction using a catheter-tensioning device (CTD) without cautery was used, ranging from 0.8% to 7.8% in prostates ranging from 20 to 280 mL. However, when standard traction (taping the catheter to the leg, gauze knot synched up to the meatus, or no traction at all) was used and where the surgeon performed bladder neck cauter only when necessary, the risk of transfusion was 1.4–2.5% in prostates ranging from 20 to 280 mL.

Conclusions
While the athermal subgroup with robust traction with a CTD had comparable transfusion rates for smaller prostates, the risk increased significantly as prostate volume increased. With standard traction methods and selective bladder neck cauter, the risk of transfusion was reduced to 1.9% across all prostate sizes.

Keywords
benign prostatic hyperplasia, transfusions, lower urinary tract symptoms, robotic, Aquablation therapy

Introduction
Surgical management remains the cornerstone of treating moderate-to-severe LUTS refractory to lifestyle changes and medical management. TURP has long been the comparator to new technologies, such as photoselective vapourisation (PVP) and endoscopic enucleation of the prostate (EEP), although open simple prostatectomy remains a standard surgical option for larger glands and complex pathologies for most surgeons. While each modality has inherent strengths and weaknesses, all modalities require a keen focus on postoperative bleeding management to avoid significant drops in haemoglobin that require a blood transfusion. TURP is a highly effective treatment, yet presents technical challenges in larger prostate volumes when the procedure time exceeds 90 min resulting in a 7% transfusion rate [1]. A more contemporary analysis was done of 31 813 patients who underwent TURP and concluded longer surgical duration was
associated with increased odds of any complication and, specifically, blood transfusion after controlling for age, race, comorbidities, American Society of Anesthesia (ASA) class, type of anaesthesia administered, and trainee involvement [2]. PVP has been shown to have a low bleeding risk; however, in larger prostates, data show that the number of conversions to TURP in the operating room due to bleeding [3–5] is significantly higher. EEP is the only technique that can remove all of the prostate tissue up to the capsule through an endoscopic approach. It is effective for prostates of any size; however, the learning curve is so challenging [6] that only a small minority of surgeons have adopted this technique. Published data have shown transfusion rates of 4% for holmium enucleation of the prostate (HoLEP) [7,8]. Finally, open prostatectomy is often the go to option for larger prostates for surgeons who are not trained in EEP, but is a highly invasive surgery. Intraoperative haemostasis is achieved with electrocautery, yet studies report transfusion rates as high as 24% [7,9].

Aquablation therapy is a new endoscopic, transurethral procedure for LUTS due to BPH. Aquablation therapy leverages real-time ultrasound imaging to enable the surgeon to personalise the resection path for each patient under direct visualisation. This enables optimal resection while avoiding critical anatomical areas. The robotic technology autonomously ablates the prostate tissue using a heat-free waterjet along the custom resection path. The autonomous robotic technology ensures the procedure is consistent and reproducible, regardless of surgeon skill or experience, allowing for a shallow learning curve. The heat-free waterjet uses room temperature saline to ablate prostate tissue within the confines of the resection path, thereby eliminating heat-induced complications. Seven different clinical trials have been completed showing that Aquablation therapy provides effective and consistent outcomes across all prostate sizes with a minimal learning curve, while maintaining low complication rates and high patient satisfaction. The initial results of Aquablation therapy have been promising [10–14]. Aquablation has been included in the AUA guidelines for the surgical management of BPH/LUTS (for prostate volumes >30/<80 mL) in 2019.

A variety of techniques have been employed for haemostasis management, including an integrated 3–5 W coagulating laser, roller-ball or loop electrocautery, and athermal traction utilising either a specially designed catheter-tensioning device (CTD) or tape or gauze traction. The CTD is an external catheter accessory mounted at the pubis that maintains and holds calibrated tension with a traction force of 600–1500 g on the urinary catheter, with the aim to eliminate the need of cautery. The purpose of the present analysis was to evaluate these different haemostatic techniques on transfusion rates following Aquablation therapy to determine if athermal methods are as effective in preventing postoperative transfusions as the use of selective bladder neck cautery across various prostate volumes. The basis for the present analysis was an observed chronological transfusion rate increase across various data sets (Table 1).

### Patients and methods

The AQUABEAM Robotic System (PROCEPT BioRobotics, Redwood City, CA, USA) used to perform Aquablation therapy utilising a maximum waterjet resection depth and treatment angle of 24.3 mm and 225°, respectively, and a resection length of 70 mm was first used in 2014 [15]. Prior generations of the robot had a shorter maximum resection depth and are excluded from this analysis. Data from seven clinical studies, sponsored by PROCEPT BioRobotics, along with four high-volume early commercial users of the technology were included. The clinical studies were AQUABEAM India Study for the Treatment of Benign Prostatic Hyperplasia (ABS; ClinicalTrials.gov Identifier: NCT03167294), Acute Haemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia (AHA; NCT03125863), AHA II (NCT03125889), Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue (WATER; NCT02505919), WATER II (NCT03123250), Français-WATER (NCT03191734), and OPEN WATER (NCT02974751). The four commercial centres that contributed consecutive data were Asklepios Klinikum Harburg (author T.B.), American University of Beirut Medical Center (A.E.), Clinique Pasteur (V.M.), and Hospital Quirón Salud Barcelona (E.R.).

The procedural data collected were prostate volume and haemostasis method used (athermal, bladder neck cautery after Aquablation, and method of traction). Traction was defined as robust if set to a tension of >600 g (5.9 N) with a CTD or defined as standard, which was traction using the following methods: tapping the catheter to the leg, gauze knot

### Table 1 Transfusion rates by data set organised chronologically (left to right).

|               | Pre-WATER | WATER | WATER II | Commercial |
|---------------|-----------|-------|----------|------------|
|               | Standard  | Robust| Standard | Robust     | Standard  | Robust  |
| N             | 79        | 0     | 135      | 0          | 101       | 108     | 378     |
| Prostate size, mL, median (range) | 38 (28–133) | 52 (25–80) | 105 (80–150) | 9.9       | 9.9       | 9.9     | 9.9     |
| Transfusion rate, % | 1.3       | 1.5   | 1.5      | 2.8        | 2.8       | 2.8     | 4.0     |
synched up to the meatus or no traction at all. All patients received continuous bladder irrigation as per hospital standard practice.

Statistical analysis

The data were grouped by prostate volume tertiles to observe transfusion rates across small, medium, and large prostates by haemostasis methods. Logistic regression modelling was used to assess the impact of prostate size and haemostasis method to assess postoperative haemoglobin changes. Exploratory modelling using interaction terms was performed. All statistical analysis was performed using R (R Foundation for Statistical Computing, Vienna, Austria) [7].

Results

In all, 801 patients were treated with Aquablation therapy from 2014 to early 2019 from the data sources described in the Methods section (Table 2). The mean (SD, range) prostate volume was 67 (33, 20–280) mL. The small prostate tertile had a mean (SD, range) prostate volume of 35 (7, 20–48) mL. The medium prostate tertile had a mean (SD, range) prostate volume of 104 (26, 77–280) mL.

Transfusions were reported in 31 (3.9%) patients. Most transfusions occurred before hospital discharge and none of the transfusions occurred beyond 30 days. Figure 1 compares the transfusion rate comparing robust traction vs standard traction across prostate volume tertiles. While the transfusion rate is similar in small prostates, the transfusion rate increased 2–5-fold with robust traction over medium and large volumes. In all, 35% of the standard traction method procedures utilised focal bladder neck cautery. Figure 2 shows a similar rate of transfusion across all prostate sizes.

Haemoglobin changes followed a similar pattern, with statistically significantly larger predicted perioperative drops in patients with larger prostates, and a lesser change when cautery was used (all P < 0.001). Predicted haemoglobin changes were lowest when standard traction was used along with bladder neck cautery (Fig. 3).

Discussion

Intraoperative haemostasis management is a critical part of any prostate resective surgery to minimise bleeding events. TURP, PVP, EEP, and open simple prostatectomy all rely on intraoperative cautery by a monopolar device or laser.
Inclusion criteria was a prostate volume of 80 mL. In the WATER study [10], where one of the immediate after Aquablation, even in the largest tertile of traction and when focal cautery at the bladder neck was used events. There were fewer bleeding events without robust use of athermal robust traction, and the rate of bleeding suggests that there is a relationship between prostate volume, management with Aquablation therapy, and the results of the use of cautery may be an effective haemostasis management technique. This analysis represents a significant step in the evolution of the AQUABEAM technology. We anticipate further refinements in clinical practice and studies to shed further light on optimal haemostatic techniques to complement the impressive volume-independent, waterjet ablation of Aquablation.

Our present study is subject to limitations, including its retrospective nature and unbalanced patient numbers in each group. Further, during the various clinical trials there were limitations on the type of haemostatic methods utilised. Despite this, we had a very large cohort for the present study and our findings include real-world usage. Finally, all procedures in the present study were performed by expert surgeons who were well beyond the learning curve, which could limit the generalisability of our findings to less-experienced surgeons. Notwithstanding, this is to our knowledge the first study to date examining various haemostatic methods and postoperative transfusions.

Conclusions

While the athermal subgroup that received robust traction with a CTD had comparable transfusion rates for smaller prostates, the risk increased significantly as prostate volume increased. With standard traction methods and selective bladder neck cautery, the risk of transfusion is reduced to 1.9% across all prostate sizes.

Conflict of interest

All authors are investigators for PROCEPT.

Source of funding

PROCEPT BioRobotics funded all the clinical trials.

References

1 Mebus WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 2002; 167: 999–1003
2 Riedinger CB, Fantus RJ, Matulewicz RS, Werntz RP, Rodriguez JF, Smith ND. The impact of surgical duration on complications after transurethral resection of the prostate: an analysis of NSQIP data. Prostate Cancer Prostatic Dis 2019; 22: 303–8
3 Valdivieso R, Hueber PA, Meskawi M et al. Multicenter international experience of 180W LBO laser photo-vaporization in men with extremely large prostates (prostate volume>200cc): is there a size limit? Eur Urol Suppl 2018; 17: e191
4 Lanchon C, Fiard G, Long JA et al. Open prostatectomy versus 180-W XPS GreenLight laser vaporization: long-term functional outcome for prostatic adenomas>80 g. Prog Urol 2018; 28: 180–7
5 Hueber PA, Liberman D, Ben-Zvi T et al. 180 W vs 120 W lithium triborate photoselective vaporization of the prostate for benign prostatic hyperplasia: a global, multicenter comparative analysis of perioperative treatment parameters. Urology 2013; 82: 1108–13
6 Robert G, Cornu JN, Fourmarier M et al. Multicentre prospective evaluation of the learning curve of holmium laser enucleation of the prostate (HoLEP). BJU Int 2016; 117: 495–9
7 Gratzke C, Schlenker B, Seitz M et al. Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. J Urol 2007; 177: 1419–22
8 Desai M, Bidair M, Bhojani N et al. WATER II (80–150 mL) procedural outcomes. BJU Int 2019; 123: 106–12
9 Pariser JJ, Pearce SM, Patel SG, Bales GT. National trends of simple prostatectomy for benign prostatic hyperplasia with an analysis of risk factors for adverse perioperative outcomes. Urology 2015; 86: 721–6
10 Gilling P, Barber N, Bidair M et al. WATER: a double-blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. J Urol 2019; 199: 1252–61
11 Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-year results. J Urol 2017; 197: 1565–72
12 Gilling P, Barber N, Bidair M et al. Two-year outcomes after aquablation compared to TURP: efficacy and ejaculatory improvements sustained. Adv Ther 2019; 36: 1326–36
13 Desai M, Bidair M, Zorn KC et al. Aquablation for benign prostatic hyperplasia in large prostates (80–150 mL): 6-month results from the WATER II trial. BJU Int 2019; 124: 321–8
14 Bhojani N, Bidair M, Zorn K, Roehrborn C. Aquablation for benign prostatic hyperplasia in large prostates (80–150cc): 1-year results. Urology 2019; 129: 1–7
15 Desai MM. Aquablation therapy for symptomatic BPH – single center experience in 47 patients. BJU Int 2018; 121: 945–51
16 Bach T, Giannakis I, Bachmann A et al. Aquablation of the prostate: single-center results of a non-selected, consecutive patient cohort. World J Urol 2019; 37: 1369–75
17 Bhojani N, Nguyen DD, Kaufman RP, Elterman D, Zorn KC. Comparison of < 100 cc prostates and > 100 cc prostates undergoing aquablation for benign prostatic hyperplasia. World J Urol 2019; 37: 1361–8

Correspondence: Dean Elterman, Division of Urology, University Health Network, Toronto Western Hospital, University of Toronto, Room 317, 8th floor, Main Pavilion, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada.
e-mail: dean.elterman@uhn.ca

Abbreviations: CTD, catheter-tensioning device; EEP, endoscopic enucleation of the prostate; HoLEP, holmium enucleation of the prostate; PVP, photoselective vaporisation; WATER, Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue.
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Elterman, D; Bach, T; Rijo, E; Misrai, V; Anderson, P; Zorn, KC; Bhojani, N; El Hajj, A; Chughtai, B; Desai, M

Title:
Transfusion rates after 800 Aquablation procedures using various haemostasis methods

Date:
2020-01-24

Citation:
Elterman, D., Bach, T., Rijo, E., Misrai, V., Anderson, P., Zorn, K. C., Bhojani, N., El Hajj, A., Chughtai, B. & Desai, M. (2020). Transfusion rates after 800 Aquablation procedures using various haemostasis methods. BJU INTERNATIONAL, 125 (4), pp.568-572. https://doi.org/10.1111/bju.14990.

Persistent Link:
http://hdl.handle.net/11343/247318

File Description:
published version

License:
CC BY-NC